Effects of glucose and insulin on secretion of amyloid-β by human adipose tissue cells

Obesity

Volumn 24, Issue 7, 2016, Pages 1471-1479

  Tharp, William G ^a   Gupta, Dhananjay ^a   Smith, Joshua ^b   Jones, Karen P ^b   Jones, Amanda M ^b   Pratley, Richard E ^b  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b FLORIDA HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; BETA SECRETASE; GAMMA SECRETASE; GLUCOSE; GLUCOSE TRANSPORTER 4; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; PRESENILIN 2; PROTEIN AKT 1; PROTEIN KINASE B; SECRETASE; UNCLASSIFIED DRUG;

ADIPOCYTE; ADIPOSE TISSUE CELL; ADULT; ALZHEIMER DISEASE; ARTICLE; CELL COUNT; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; LIPID COMPOSITION; MALE; MICROANATOMY; MICRODIALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; STROMAL VASCULAR CELL;

EID: 84976615205     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1002/oby.21494     Document Type: Article

References (40)

1. Craft S. The role of metabolic disorders in Alzheimer disease and vascular dementia: two roads converged. Arch Neurol 2009;66:300-305.
2. Luchsinger JA. Adiposity, hyperinsulinemia, diabetes and Alzheimer's disease: an epidemiological perspective. Eur J Pharmacol 2008;585:119-129.
3. Rios JA, Cisternas P, Arrese M, Barja S, Inestrosa NC. Is Alzheimer's disease related to metabolic syndrome? A Wnt signaling conundrum. Prog Neurobiol 2014;121:125-146.
4. Danaei G, Finucane MM, Lu Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 2011;378:31-40.
5. Finucane MM, Stevens GA, Cowan MJ, et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet 2011;377:557-567.
6. Mayeux R, Stern Y. Epidemiology of Alzheimer disease. Cold Spring Harb Perspect Med 2012;2:a006239.
7. Johnson KA, Fox NC, Sperling RA, Klunk WE. Brain imaging in Alzheimer disease. Cold Spring Harb Perspect Med 2012;2:a006213.
8. Talbot K, Wang HY, Kazi H, et al. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 2012;122:1316-1338.
9. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002;297:353-356.
10. Muller UC, Zheng H. Physiological functions of APP family proteins. Cold Spring Harb Perspect Med 2012;2:a006288.
11. Masters CL, Selkoe DJ. Biochemistry of amyloid beta-protein and amyloid deposits in Alzheimer disease. Cold Spring Harb Perspect Med 2012;2:a006262.
12. Coulson EJ, Paliga K, Beyreuther K, Masters CL. What the evolution of the amyloid protein precursor supergene family tells us about its function. Neurochem Int 2000;36:175-184.
13. Takeda S, Sato N, Uchio-Yamada K, et al. Elevation of plasma beta-amyloid level by glucose loading in Alzheimer mouse models. Biochem Biophys Res Commun 2009;385:193-197.
14. Zhang Y, Zhou B, Zhang F, et al. Amyloid-beta induces hepatic insulin resistance by activating JAK2/STAT3/SOCS-1 signaling pathway. Diabetes 2012;61:1434-1443.
15. Needham BE, Wlodek ME, Ciccotosto GD, et al. Identification of the Alzheimer's disease amyloid precursor protein (APP) and its homologue APLP2 as essential modulators of glucose and insulin homeostasis and growth. J Pathol 2008;215:155-163.
16. Cao D, Lu H, Lewis TL, Li L. Intake of sucrose-sweetened water induces insulin resistance and exacerbates memory deficits and amyloidosis in a transgenic mouse model of Alzheimer disease. J Biol Chem 2007;282:36275-36282.
17. Ho L, Qin W, Pompl PN, et al. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J 2004;18:902-904.
18. Jimenez-Palomares M, Ramos-Rodriguez JJ, Lopez-Acosta JF, et al. Increased Abeta production prompts the onset of glucose intolerance and insulin resistance. Am J Physiol Endocrinol Metab 2012;302:E1373-E1380.
19. Takeda S, Sato N, Uchio-Yamada K, et al. Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Abeta deposition in an Alzheimer mouse model with diabetes. Proc Natl Acad Sci USA 2010;107:7036-7041.
20. Fishel MA, Watson GS, Montine TJ, et al. Hyperinsulinemia provokes synchronous increases in central inflammation and beta-amyloid in normal adults. Arch Neurol 2005;62:1539-1544.
21. Gasparini L, Gouras GK, Wang R, et al. Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling. J Neurosci 2001;21:2561-2570.
22. Farris W, Mansourian S, Chang Y, et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci USA 2003;100:4162-4167.
23. Qiu WQ, Walsh DM, Ye Z, et al. Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J Biol Chem 1998;273:32730-32738.
24. Xie L, Helmerhorst E, Taddei K, Plewright B, Van Bronswijk W, Martins R. Alzheimer's beta-amyloid peptides compete for insulin binding to the insulin receptor. J Neurosci 2002;22:RC221.
25. Lee YH, Tharp WG, Maple RL, Nair S, Permana PA, Pratley RE. Amyloid precursor protein expression is upregulated in adipocytes in obesity. Obesity (Silver Spring) 2008;16:1493-1500.
26. Skurk T, Hauner H. Primary culture of human adipocyte precursor cells: expansion and differentiation. Methods Mol Biol 2012;806:215-226.
27. Castellano JM, Kim J, Stewart FR, et al. Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance. Sci Transl Med 2011;3:89ra57.
28. Citron M, Vigo-Pelfrey C, Teplow DB, et al. Excessive production of amyloid beta-protein by peripheral cells of symptomatic and presymptomatic patients carrying the Swedish familial Alzheimer disease mutation. Proc Natl Acad Sci USA 1994;91:11993-11997.
29. Buren J, Lindmark S, Renstrom F, Eriksson JW. In vitro reversal of hyperglycemia normalizes insulin action in fat cells from type 2 diabetes patients: is cellular insulin resistance caused by glucotoxicity in vivo? Metabolism 2003;52:239-245.
30. Jansson PA, Larsson A, Smith U, Lonnroth P. Glycerol production in subcutaneous adipose tissue in lean and obese humans. J Clin Invest 1992;89:1610-1617.
31. Takeda S, Sato N, Uchio-Yamada K, et al. Oral glucose loading modulates plasma beta-amyloid level in Alzheimer's disease patients: potential diagnostic method for Alzheimer's disease. Dement Geriatr Cogn Disord 2012;34:25-30.
32. Townsend M, Mehta T, Selkoe DJ. Soluble Abeta inhibits specific signal transduction cascades common to the insulin receptor pathway. J Biol Chem 2007;282:33305-33312.
33. Zhao WQ, De Felice FG, Fernandez S, et al. Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J 2008;22:246-260.
34. Brannmark C, Nyman E, Fagerholm S, et al. Insulin signaling in type 2 diabetes - experimental and modeling analyses reveal mechanisms of insulin resistance in human adipocytes. J Biol Chem 2013;288:9867-9880.
35. Pereira MJ, Palming J, Rizell M, et al. mTOR inhibition with rapamycin causes impaired insulin signalling and glucose uptake in human subcutaneous and omental adipocytes. Mol Cell Endocrinol 2012;355:96-105.
36. Renstrom F, Buren J, Svensson M, Eriksson JW. Insulin resistance induced by high glucose and high insulin precedes insulin receptor substrate 1 protein depletion in human adipocytes. Metabolism 2007;56:190-198.
37. Back K, Brannmark C, Stralfors P, Arnqvist HJ. Differential effects of IGF-I, IGF-II and insulin in human preadipocytes and adipocytes–role of insulin and IGF-I receptors. Mol Cell Endocrinol 2011;339:130-135.
38. Cleveland-Donovan K, Maile LA, Tsiaras WG, Tchkonia T, Kirkland JL, Boney CM. IGF-I activation of the AKT pathway is impaired in visceral but not subcutaneous preadipocytes from obese subjects. Endocrinology 2010;151:3752-3763.
39. Chai SP, Fong JC. Mechanism of inhibition of insulin-stimulated glucose transport by 4-bromocrotonic acid in 3T3-L1 adipocytes. Cell Signal 2003;15:269-277.
40. Hresko RC, Mueckler M. mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J Biol Chem 2005;280:40406-40416.